Search

Zai Lab Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

19.2 -6.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.93

Max

20.49

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-607K

-51M

Pardavimai

-28M

100M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-51.215

Darbuotojai

1,784

EBITDA

4.1M

-44M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+64.63% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-67M

2.3B

Ankstesnė atidarymo kaina

25.22

Ankstesnė uždarymo kaina

19.2

Naujienos nuotaikos

By Acuity

100%

0%

319 / 340 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-23 23:51; UTC

News

Cavco Industries Inc. announced its first-quarter earnings release date, contributing to positive investor sentiment. Shares are higher in after-market trading.

2026-07-23 23:51; UTC

News

Scholastic Corp shares fell in after-market trading following fourth-quarter results, where revenue of $476.1 million missed expectations and net income dropped to $9.4 million.

2026-07-23 23:51; UTC

News
Social Media

Leidos Holdings shares are lower in after-market trading amid concerns over long-term revenue growth, despite a backlog of $48.37 billion.

2026-07-23 23:51; UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

2026-07-23 23:51; UTC

News

PayPal shares are lower in after-market trading as Stripe and Advent assess acquisition options, with prior offers reportedly considered insufficient.

2026-07-23 23:46; UTC

News

Delek US Holdings Inc declared a quarterly dividend of $0.255 per share, contributing to shares trading higher in after-market hours.

2026-07-23 23:46; UTC

News
Social Media

CSX Corp shares rose in after-market trading following stronger-than-expected second-quarter results, with earnings of $0.54 per share and revenue of $3.94 billion.

2026-07-23 23:41; UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

2026-07-23 23:41; UTC

Event
News

GE Healthcare appointed George Newcomb as interim CFO and reported $5.30 billion in second-quarter revenue, with shares higher in after-market trading.

2026-07-23 23:41; UTC

News

Albertsons Companies reported revenue growth in Q1 2026, despite margin contraction. Shares are modestly higher in after-market trading since Thursday's close.

2026-07-23 23:41; UTC

News

Charter Communications launched a private offer to exchange notes, potentially issuing up to $1.75 billion in new notes, with shares trading higher in after-market hours.

2026-07-23 23:31; UTC

Social Media
Correlated Moves
News

Newmont Corporation's adjusted EPS of $2.10 missed estimates, with revenue at $6.12 billion, leading to a decline in after-market trading.

2026-07-23 23:31; UTC

News

Appian Corp's digital application update for community services workers supports over 210,000 and processed more than $100 million, boosting shares in after-market hours.

2026-07-23 23:26; UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

2026-07-23 23:26; UTC

News

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

2026-07-23 23:21; UTC

News

Robert Half shares are trading lower in after-market hours following a second-quarter revenue decline to $1.336 billion and a cautious outlook for Q3.

2026-07-23 23:21; UTC

Social Media
News

Maxlinear Inc's shares fell in after-hours trading following second-quarter results, with net revenue of $168.8 million but diluted earnings of $0.02 per share.

2026-07-23 23:21; UTC

News

McKesson Corp shares fell in after-market trading amid weakness in the Health Care Distributors sector, despite strong annual revenue and earnings growth.

2026-07-23 23:02; UTC

ETF Constituents
News

Vanguard Large-Cap ETF gains after hours, supported by major holdings like Microsoft and Tesla, despite broader market declines from new tariffs announced by President Trump.

2026-07-23 23:02; UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I rises in after-market trading, supported by positive sentiment from Intel's projected capital expenditures exceeding $20 billion.

2026-07-23 23:02; UTC

Social Media
News

RingCentral's revenue of $657 million surpassed estimates, prompting a raised full-year guidance. Shares are higher in after-market trading, rebounding from an earlier session low.

2026-07-23 23:02; UTC

Correlated Moves
News

Ovintiv Inc reported second-quarter earnings that missed expectations, with an EPS of $1.62. Shares are lower in after-market trading following the results.

2026-07-23 23:02; UTC

Social Media
News

Appfolio Inc shares are lower in after-market trading following second-quarter earnings. Revenue guidance of $1.117 billion to $1.127 billion fell short of expectations.

2026-07-23 23:02; UTC

News

Selective Insurance Group shares fell in after-hours trading following mixed second-quarter results, despite net income of $127.1 million and revenue of $1.39 billion.

2026-07-23 23:02; UTC

News
Social Media

Comfort Systems USA reported strong Q2 earnings and revenue, but shares are trading lower in after-market hours, indicating a shift in market sentiment.

2026-07-23 23:02; UTC

Social Media
News

Amkor Technology announced a $1.5 billion partnership with NVIDIA to enhance packaging capacity, boosting shares significantly in after-market hours.

2026-07-23 23:02; UTC

Correlated Moves
News

ServiceNow shares are higher in after-market hours as Macquarie raised its price target to $110, reflecting positive market sentiment and sector dynamics.

2026-07-23 23:02; UTC

Social Media
News

Intel Corp reported second-quarter revenue of $16.1 billion, exceeding expectations. The positive outlook has driven shares higher in after-market hours.

2026-07-23 23:02; UTC

News

Boeing Co shares are lower in after-market trading after announcing the divestiture of its stake in HRL Laboratories, LLC, amid broader market pressures.

2026-07-23 23:01; UTC

News
Social Media
Event

Tenet Healthcare Corp reported second-quarter adjusted EPS of $6.12, exceeding estimates. Shares are trading higher in after-market hours following strong earnings and raised guidance.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

64.63% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD  64.63%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

319 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat